Alnylam Pharmaceuticals enters the back half of August carrying scars from a brutal July earnings print — and a Street that remains constructive but is methodically resetting its expectations lower.
The tension is straightforward: analysts overwhelmingly rate the stock a buy, yet nearly every firm that has touched the model in the past three weeks has trimmed its target price, some sharply. The consensus target sits at $370, roughly 62% above the current price of $228.61. But that gap reflects prior-period targets that haven't fully adjusted, not fresh conviction. BMO Capital initiated coverage this week at $318 with an Outperform, which is telling — a new buyer at the table, but one who entered well below where the rest of the Street was anchored just a month ago. Wells Fargo cut its target to $256 from $316 while holding Equal-Weight; Barclays trimmed to $450 from $527; JP Morgan moved to $375 from $400, both keeping positive ratings. Raymond James was the outlier, upgrading to Strong Buy while leaving the $420 target unchanged. The direction of travel is clear: bulls are staying long but quietly marking down their models.
The reason for the resets is not subtle. Alnylam's Q2 earnings, released July 30, triggered a 28% single-day drop — the stock fell a further 25% over the following week, its worst five-day post-earnings move in recent memory. The next release is October 29, and the market appears to be recalibrating around that timeline. The bear case centers on the Phase 3 CARDIO-TTRansform trial disappointment for Onpattro, competitive pressure from AMVUTTRA and nucresiran, and a forward earnings picture that has deteriorated meaningfully: the EPS momentum factor scores rank in the 24th to 39th percentile, and forward EPS growth is running deeply negative year-on-year. The bull case rests on the TTR franchise's long-term durability, pipeline optionality across new tissue types, and a balance sheet that remains solid — the ORTEX quality score is one of the cleaner reads in the biotech space, with a high f_score and low distress indicators.
Positioning in the lending market is almost entirely uninformative right now — which is itself a data point. Short interest has pulled back 8% on the week to roughly 4% of the free float, continuing a decline from the 5.7% range seen in early August. Borrow costs are negligible at 0.48%, and availability is extraordinarily loose at over 2,300% — meaning there are roughly 23 shares available to borrow for every one already lent out. Bears had the opportunity to press the short after the July collapse and largely did not; the current short position is actually lighter than it was before the earnings disaster. That is not a crowded short.
Options sentiment has shifted modestly in a bullish direction, though not dramatically. The put/call ratio dropped to 0.51, about 1.5 standard deviations below its 20-day average of 0.55. Taken with the light short positioning, it suggests the investor base has absorbed the July shock without panicking into aggressive hedges or mass shorting — a degree of composure that reflects a holder base anchored by long-term institutional owners. Capital Research holds 15.7% of shares, FMR (Fidelity) 10.7%, and BlackRock 8.2% — all of whom added modestly through July.
The stock has reclaimed 3.4% this week, closing at $228.61, but remains down nearly 15% over the past month. The next moment of reckoning is October 29 — the question by then will be whether Alnylam can show any evidence of commercial stabilization in its TTR franchise or early signs that its pipeline can fill the gap that the CARDIO-TTRansform miss opened up.
See the live data behind this article on ORTEX.
Open ALNY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
